|
|
3155 Porter Drive
Palo Alto, CA 94304-1213 USA
phone:(650) 475-3100
fax:650-475-3101
|
|
| Symbol |
STEM |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.stemcellsinc.com/
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| The Company is a biopharmaceutical company developing novel stem cell therapies. |
|
| Management |
| Martin McGlynn, President and Chief Executive Officer; Ann Tsukamoto, Ph.D., Chief Operating Officer; Rodney Young, Chief Financial Officer & VP, Finance and Administration; Stephen Huhn, M.D., F.A.C.S., F.A.A.P., VP, Head of the Neural Program; Elizabeth Leininger, Ph.D., VP, Regulatory Affairs and Quality Assurance; Maria Millan, M.D., F.A.C.S., VP, Head of the Liver Program; Ken Stratton , General Counsel; Nobuko Uchida, Ph.D., VP, Stem Cell Biology |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
StemCells, Inc. is a biopharmaceutical company that is developing novel stem cell therapies designed to treat human diseases and disorders.
The Company is engaged in research that would use stem and progenitor cells to treat and possibly cure, human diseases and injuries, including neurodegenerative diseases, demyelinating disorders, spinal cord injuries, stroke, hepatitis, chronic liver failure and diabetes. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members